These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27040700)

  • 1. Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade.
    Herman SE; Wiestner A
    Semin Oncol; 2016 Apr; 43(2):222-32. PubMed ID: 27040700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions.
    Bertilaccio MT; Scielzo C; Simonetti G; Ten Hacken E; Apollonio B; Ghia P; Caligaris-Cappio F
    Leukemia; 2013 Mar; 27(3):534-40. PubMed ID: 23041721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia.
    Gimenez N; Tripathi R; Giró A; Rosich L; López-Guerra M; López-Oreja I; Playa-Albinyana H; Arenas F; Mas JM; Pérez-Galán P; Delgado J; Campo E; Farrés J; Colomer D
    Sci Rep; 2020 Dec; 10(1):22153. PubMed ID: 33335123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.
    Liu PP; Liu J; Jiang WQ; Carew JS; Ogasawara MA; Pelicano H; Croce CM; Estrov Z; Xu RH; Keating MJ; Huang P
    Oncogene; 2016 Oct; 35(43):5663-5673. PubMed ID: 27065330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using the biology of chronic lymphocytic leukemia to choose treatment.
    Hillmen P
    Hematology Am Soc Hematol Educ Program; 2011; 2011():104-9. PubMed ID: 22160020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.
    Herishanu Y; Katz BZ; Lipsky A; Wiestner A
    Hematol Oncol Clin North Am; 2013 Apr; 27(2):173-206. PubMed ID: 23561469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the chronic lymphocytic leukemia microenvironment in vitro.
    Crassini K; Shen Y; Mulligan S; Giles Best O
    Leuk Lymphoma; 2017 Feb; 58(2):266-279. PubMed ID: 27756161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine models for chronic lymphocytic leukaemia.
    Michie AM; Nakagawa R; McCaig AM
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1009-12. PubMed ID: 17956265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model.
    Mohammad RM; Mohamed AN; Hamdan MY; Vo T; Chen B; Katato K; Abubakr YA; Dugan MC; al-Katib A
    Leukemia; 1996 Jan; 10(1):130-7. PubMed ID: 8558918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on signal inhibitors in chronic lymphocytic leukemia.
    Boddu P; Jain N
    Clin Adv Hematol Oncol; 2018 Apr; 16(4):279-288. PubMed ID: 29742083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
    Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
    Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.
    Matas-Céspedes A; Vidal-Crespo A; Rodriguez V; Villamor N; Delgado J; Giné E; Roca-Ho H; Menéndez P; Campo E; López-Guillermo A; Colomer D; Roué G; Wiestner A; Parren PW; Doshi P; van Bueren JL; Pérez-Galán P
    Clin Cancer Res; 2017 Mar; 23(6):1493-1505. PubMed ID: 27637890
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups.
    Decker S; Zwick A; Khaja Saleem S; Kissel S; Rettig A; Aumann K; Dierks C
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31842407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide-donating acetylsalicylic acid induces apoptosis in chronic lymphocytic leukemia cells and shows strong antitumor efficacy in vivo.
    Razavi R; Gehrke I; Gandhirajan RK; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
    Clin Cancer Res; 2011 Jan; 17(2):286-93. PubMed ID: 21097689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
    Hartmann TN; Pleyer L; Desch P; Egle A; Greil R
    Discov Med; 2009 Oct; 8(42):157-64. PubMed ID: 19833065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapies for chronic lymphocytic leukemia in the 21st century.
    Byrd JC; Waselenko JK; Keating M; Rai K; Grever MR
    Semin Oncol; 2000 Oct; 27(5):587-97. PubMed ID: 11049025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising therapies for the treatment of chronic lymphocytic leukemia.
    Morabito F; Recchia AG; Vigna E; De Stefano L; Bossio S; Morabito L; Pellicanò M; Palummo A; Storino F; Caruso N; Gentile M
    Expert Opin Investig Drugs; 2015 Jun; 24(6):795-807. PubMed ID: 25728009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Anticancer Activity of Acacetin Against Chronic Lymphocytic Leukemia Using Both In Vivo and In Vitro Methods: Key Role of Oxidative Stress and Cancerous Mitochondria.
    Salimi A; Roudkenar MH; Sadeghi L; Mohseni A; Seydi E; Pirahmadi N; Pourahmad J
    Nutr Cancer; 2016; 68(8):1404-1416. PubMed ID: 27779444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
    Hilal T; Gea-Banacloche JC; Leis JF
    Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.